HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 4% as the company conducted its first A-share buyback; institutions are bullish that the non-oncology segment will continue to contribute incremental product-side growth.

Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 4%, up 3.2% as of press time, at HK$45.8, with a turnover of HK$59.5373 million. On the news front, Jiangsu Hengrui Pharmaceuticals announced that on September 17, 2026, it spent RMB 14.5036 million to repurchase 335,000 A-shares. A research report by Zheshang noted that in 2026H1, the company's innovative drug sales revenue reached RMB 8.809 billion, up 16.38% year-on-year, accounting for 63.16% of pharmaceutical sales revenue. Among this, revenue from non-oncology innovative products was RMB 2.545 billion, up 73.97% year-on-year, contributing about 87% of the incremental revenue from innovative drugs, with growth mainly driven by Hengrui's henagliflozin as well as newly medical insurance-included ivarmacitinib, vunakizumab, and recaticimab. The bank believes that as newly medical insurance-included products gradually ramp up, it is bullish on the non-oncology segment continuing to contribute product-side growth.